Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE.

Autor:	Bacon, C. L.1, Singleton, E.1, Brady, B.2, White, B.2, Nolan, B.1, Gilmore, R. M.1, Ryan, C.3, Keohane, C.1, Vince Jenkins, P.1,4, O'Donnell, J. S.1,4 jodonne@tcd.ie
Zdroj:	Haemophilia. May2011, Vol. 17 Issue 3, p407-411. 5p. 1 Diagram, 1 Chart.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu